The STOPBAG2 scoring instrument, which incorporates sleep-related symptoms and continuous variables for age and BMI, offers greater discriminatory power for predicting all levels of OSA severity in adults with epilepsy.
Researchers find that many Huntington disease specialist clinics do not have the resources available to administer DMTs appropriately with an intrathecal strategy.
Add-on cannabidiol was found to be safe and effective for patients with Lennox Gastaut Syndrome.
Investigators have identified a novel genetic association for tau deposition, with resistance to entorhinal cortex (ERC) deposition, in older adults.
In patients with SMA, treatment with nusinersen was associated with improvement in health-related quality of life and reduced impact on caregivers.
Youth with a history of status migranosus are more likely to experience an increase of >4 headache days per month during a follow-up evaluation.
Certain components of metabolic syndrome may be more common in patients with Parkinson disease who are carriers of an LRRK2 mutation compared with other PD etiologies.
Prolonged delays from ICH symptom onset to hospital presentation is associated with worse functional outcomes at 3 months, compared with earlier presentation.
Researchers sought to validate traumatic encephalopathy syndrome criteria for the diagnosis and management of patients with CTE.
Treatment with fremanezumab for episodic and chronic migraine was found to have a favorable cardiovascular safety profile in patients with and without a history of cardiovascular disease.
In patients with relapsing MS ponesimod was found to be superior to teriflunomide on annualized relapse rate, MRI activity and brain atrophy.
Pimavanserin, either alone or in conjunction with a selective serotonin reuptake inhibitor or serotonin–norepinephrine reuptake inhibitor, may improve comorbid depression symptoms in patients with Parkinson disease.
Individuals with vs without status epilepticus were found to have a greater prevalence of cardiovascular risk factors and a higher risk of developing cardiovascular diseases.
The beneficial effects of statin therapy for the prevention of ischemic stroke outweigh the potential risk for ICH associated with the treatment.
Switching from natalizumab to moderate DMT vs switching to high efficacy therapy in MS patients was associated with lower rates of no disease activity.